Welcome to our dedicated page for Ovid Therapeutics news (Ticker: $OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ovid Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ovid Therapeutics's position in the market.
Ovid Therapeutics (NASDAQ: OVID) has provided business updates and first-quarter 2024 financial results. Key highlights include the completion of two Phase 3 trials by Takeda for soticlestat, expected to treat Lennox-Gastaut and Dravet syndromes, with topline data anticipated in H1 2024. A Phase 1 trial for OV888 (GV101) has concluded, showing no serious adverse events, with Phase 2 set to begin in H2 2024. Financials reveal cash and equivalents of $90.3 million, enough to support operations into H1 2026. Revenue for Q1 2024 was $148,000, up from $66,000 in Q1 2023, despite an increased net loss of $11.7 million.
Ovid Therapeutics Inc. will be participating in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, at 3:00 p.m. ET. The company is focused on developing medicines for rare epilepsies and brain conditions. The event will be live webcasted and can be accessed through the Company’s website.